Heyman Richard A.'s Form 4 filing
Enliven Therapeutics, Inc. (ELVN) · filed Dec 21, 2023
- Accession no.
- 0001209191-23-059431
- Filed
- Dec 21, 2023
- Trade date
- Dec 19-20, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions. Open-market sales total $55.7K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Heyman Richard A.CIK 0001584759 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 19, 2023 | Common Stock | SSaleDisposed | −255 | $13.00 | −$3,315 | 149,565 | Direct | |
| Dec 20, 2023 | Common Stock | SSaleDisposed | −2,110 | $13.02F2 | −$27,472.2 | 147,455 | Direct | |
| Dec 20, 2023 | Common Stock | SSaleDisposed | −1,915 | $13.02F2 | −$24,933.3 | 29,257 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $13.00 to $13.18. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 2 transactions in Table I.